Renal cell carcinoma (RCC) is the most difficult-to-treat form of kidney cancer with a median 5-year survival of 10% under metastatic setting. In RCC, although cytoreductive nephrectomy is common, approximately 20–30% of patients will develop recurrent cancer after surgery, which highlights the need for an effective therapy. Rho-GTPases viz, Rac-1 and Cdc42 are the central regulators of cancer cell migration and invasion and thus metastasis in multiple cancer types. Hence, we elucidated the role of Ketorolac, a modulator Rho-GTPases against RCC through potentiation of tumor suppressor Par-4. The effect of Ketorolac alone and in combination on proliferation, apoptosis, cell-cycle progression, migration, tumor inhibition and their related markers were studied. Moreover, Ketorolac’s impact on metastasis by influencing Rac-1/HIF-1α/DDX3/β-catenin signalling was studied with respect to its ability to modulate the expression of tumor suppressor Par-4, and this mechanism was confirmed by siRNA knockdown studies. Ketorolac induced cytotoxicity in a panel of renal cells including patient derived tumor cells with IC50 2.8 to 9.02 mM and 0.28 to 3.8 mM in monolayer and anchorage independent clonogenic assays respectively. Ketorolac caused significant down regulation of proliferation (Ki-67, Cyclin D1, pRB and DDX3), migration/invasion (Rac-1, Cdc42, and Tiam1), and angiogenesis (HIF-1α and VEGF) markers as studied by gene and protein expression. Moreover, it caused a significant upregulation of tumor suppressor Par-4 known to be downregulated in RCC. This mechanism was further confirmed by using siRNA knockdown studies where we could demonstrate a negative relation between the expression of Par-4 and Rac-1/Cdc42. Importantly, Ketorolac alone and in combination with Sunitinib showed tumor growth inhibition (TGI) of 73% and 86% respectively in xenograft model. This anti-tumor activity was further corroborated by down regulation of Rac-1/Cdc42/HIF-1α/DDX3/β-catenin signalling. This is the first report which implicates the role of Ketorolac against RCC by acting as a small molecule secretagogue causing upregulation of Par-4 in autocrine and paracrine manner. Consequently, these findings suggest that Par-4 can serve as a valuable therapeutic target and a prognostic marker for the treatment of RCC.
Glioblastoma (GBM) is an aggressive form of brain tumor with a median survival of approximately 12 months. With no new drugs in the last few decades and limited success in clinics for known therapies, drug repurposing is an attractive choice for its treatment. Here, we examined the efficacy of pyronaridine (PYR), an anti-malarial drug in GBM cells. PYR induced anti-proliferative activity in GBM cells with IC50 ranging from 1.16 to 6.82 µM. Synergistic activity was observed when PYR was combined with Doxorubicin and Ritonavir. Mechanistically, PYR triggered mitochondrial membrane depolarization and enhanced the ROS levels causing caspase-3 mediated apoptosis. PYR significantly decreased markers associated with proliferation, EMT, hypoxia, and stemness and upregulated the expression of E-cadherin. Interestingly, PYR induced the expression of intracellular as well as secretory Par-4, a tumor suppressor in GBM cells, which was confirmed using siRNA. Notably, Par-4 levels in plasma samples of GBM patients were significantly lower than normal healthy volunteers. Thus, our study demonstrates for the first time that PYR can be repurposed against GBM with a novel mechanism of action involving Par-4. Herewith, we discuss the role of upregulated Par-4 in a highly interconnected signaling network thereby advocating its importance as a therapeutic target.
The poor prognosis of pancreatic ductal adenocarcinoma (PDAC) is attributed to tumor microenvironment driven by hypoxia regulated carbonic anhydrase IX. Our study elucidates the ability of Methazolamide, a CAIX inhibitor to sensitize resistant PDAC cells. The effect of Methazolamide alone and in combination with gemcitabine on proliferation, migration, tumor inhibition along with its impact on metastasis by influencing HIF-1α/PTEN/Glut1/Glut3 signalling through the expression of CAIX was assessed. Methazolamide induced cytotoxicity in several PDAC cells including patient derived with IC50 0.7–4.09 mM and 0.29–2.56 mM in monolayer and clonogenic assays respectively. Methazolamide alone and in combination significantly downregulated hypoxia induced expression of HIF-1α and CAIX together with proliferation (Ki-67, Cyclin D1), invasion (Rac-1, Snail), stem cell (Oct-4, Sox-2), angiogenesis (VEGF), glycolysis (Glut1, Glut3) and apoptosis (Bax, Bc1-2 and PTEN) markers in MIA PaCa-2 and PANC-1 cells. In vivo study in PAXF 546L PDX model exhibited profound tumor growth inhibition with downregulation of CD34, Oct-4, Sox-2, C-myc, Nanog, Ki-67, and Rac-1 signalling. Considering inadequate availability of effective therapeutics and importance of CAIX in processes leading to aggressive behavior of PDAC, targeting it by using Methazolamide, a pre-approved drug in combination with gemcitabine represents promising therapeutic approach specifically in metastatic settings.
Pancreatic Cancer (PC) with dismal prognosis poses a significant challenge to healthcare systems worldwide. PC is the fourth leading cause of cancer-related mortality globally and is projected to surpass lung cancer as the second foremost cause by 2030. The poor prognosis associated with PC is primarily due to the low rate of early detection, rapid progression, and limited treatment options. Chemotherapy remains a cornerstone of treatment for PC in all stages of disease. However, optimistic effects for the treatment options have been hampered by a high rate of non-responders. Resistance to treatments may arise due to various molecular mechanisms, namely intrinsic and acquired chemoresistance due to changes in genetic and epigenetic framework, drug metabolism and efflux, and tumor microenvironment. This review majorly focuses on mechanisms of cell cycle dysregulation and hypoxia induced acidosis leading to development of therapeutic resistance and poor clinical outcome. Comprehensive understanding of these resistance mechanisms could play a central role in the development of effective therapeutic strategies for improved prognosis.
7 June 2024 in Journal of Pharmacological and Toxicological Methods